Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the global immunology market, recently partnered with Lonza for the manufacture of voclosporin active pharmaceutical ingredient (API). Read More »
Genentech, a member of the Roche Group, recently announced that the primary endpoint for the Phase III HAVEN 1 study has been met. The study evaluates emicizumab prophylaxis in people 12 years of age or older with hemophilia A and inhibitors to factor VIII. Read More »
Pernix Therapeutics Holdings Inc., a pharmaceutical company specializing in pain and central nervous system conditions, recently appointed Gabriel Leung to its board of directors. Read More »
Medical technology company Zynex updated its November orders, fourth-quarter estimate and a loan forbearance agreement. Read More »
Veloxis Pharmaceuticals will establish a warrant program for its board members and its employees with the Veloxis Board of Directors exercising, in part, an authorization pursuant to the Articles of Association. Read More »
Avella has moved its operations to a new 50,000-square-foot corporate headquarters in Phoenix. Read More »
The biotech company Rebiotix Inc. recently announced that a patient has been treated for the first time with a capsule that delivers live microbes into the human intestinal tract. Read More »
AcelRx Pharmaceuticals presented results from its Phase 3 SAP303 study of ARX-04 at the 15th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine. Read More »
AzurRx BioPharma has partnered with Mayoly Spindler to begin a Phase II clinical trial to assess the safety and effectiveness of MS1819-SD for the treatment of patients who have exocrine pancreatic insufficiency that is the result of chronic pancreatitis. Read More »
Intrarosa (prasterone), which is designed for women who experience moderate to severe pain during sex, has been approved by the U.S. Food and Drug Administration. Read More »
Boehringer Ingelheim has released data from its Phase I INVICTAN-1 trial involving BI 695502, the company’s bevacizumab biosimilar candidate, which shows that the drug is a bioequivalent of Avastin, which is licensed in the U.S. and E.U. Read More »
The 2016 graduate and undergraduate student winners of the Collegiate Inventors Competition included inventions and innovations presented at the competition including the administration of therapeutic drugs at-home and engineered biological particles that destroy pesticides in residual crops. Read More »
PharmaMar has named Pascal Besman as its new chief operating officer, effective immediately. Read More »
McKesson and Health Mart support the dedication of pharmacists across all practice settings and commend the American Pharmacists Association for celebrating pharmacists’ commitment to provide customers with extraordinary service. Read More »
The Oncologic Drugs Advisory Committee, which is part of the U.S. Food and Drug Administration, has voted that Spectrum Pharmaceuticals' Qapzola has not displayed considerable indication of a more effective treatment compared to placebo for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Read More »
Array BioPharma and the U.S. Food and Drug Administration have reached an agreement regarding Special Protocol Assessment for Array’s Phase 3 trial for encorafenib and Erbitux called BEACON CRC. Read More »
Ablative Solutions' Investigational New Drug application for the Peregrine System Kit -- a catheter-based renal denervation that targets the delivery of alcohol to treat uncontrolled hypertension -- has been accepted by the U.S. Food and Drug Administration. Read More »
Annals of Oncology published the results of a brand new post-hoc analysis from two Gilotrif Phase II trials that examined dose adjustments for patients suffering from advanced non-small cell lung cancer. Read More »
Valeant Pharmaceuticals International's RELISTOR Tablets are now available for prescriptions in the United States to treat adults with chronic non-cancer pain who are experiencing opioid-induced constipation. Read More »
Zavante Therapeutics, a privately owned biopharmaceutical company that conducts late-stage clinical trials, has appointed eight infectious disease specialists to serve on its newly formed Scientific Advisory Board. Read More »
Alerts Sign-up
